Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) LATS1 Antikörper:
anti-Human LATS1 Antikörper:
anti-Rat (Rattus) LATS1 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal LATS1 Primary Antibody für IP, WB - ABIN4891893
Xiang, Gilkes, Hu, Takano, Luo, Lu, Bullen, Samanta, Liang, Semenza: Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. in Oncotarget 2015
Human Polyclonal LATS1 Primary Antibody für IF (p), IHC (p) - ABIN872292
Grijalva, Huizenga, Mueller, Rodriguez, Brazzo, Camargo, Sadri-Vakili, Vakili: Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. in American journal of physiology. Gastrointestinal and liver physiology 2014
Human Polyclonal LATS1 Primary Antibody für IHC (p), WB - ABIN391033
Iida, Hirota, Morisaki, Marumoto, Hara, Kuninaka, Honda, Kosai, Kawasuji, Pallas, Saya: Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function. in Oncogene 2004
Show all 6 Pubmed References
Thus AMOT (zeige AMOT Antikörper) is a direct substrate of Lats1/2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis.
lats genes show distinctly different expression profiles during gastrulation. lats1 is almost ubiquitously expressed through development, and lats2 (zeige LATS2 Antikörper) is more prominently expressed in the non-neural ectoderm region of zebrafish gastrula.
Study demonstrates that, in 3 different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1 and 2) in tumor cells inhibits tumor growth; data indicate a new paradigm for how tumor immunogenicity is regulated through the Hippo signaling pathway in tumor cells.
Results showed that the Hippo pathway is active in ovarian follicles and that LATS1 is required to maintain the pool of germ cells and primordial follicles.
The control of LATS activation by angiotensin II and subsequent YAP (zeige YAP1 Antikörper) localization is important for podocyte homeostasis and survival.
Willin (zeige FRMD6 Antikörper) is predominantly expressed in fibroblasts and that Willin (zeige FRMD6 Antikörper) expression activates the Hippo signaling cascade
LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization.
KIBRA (zeige WWC1 Antikörper) associates with and activates Lats (large tumor suppressor) 1 and 2 kinases by stimulating their phosphorylation on the hydrophobic motif
Lats1 enhances the activity of FOXl2 (zeige FOXL2 Antikörper) as a repressor of the StAr promoter. st
Overexpression of YAP2 (zeige YAP1 Antikörper) in cells promoted apoptosis, whereas the Mst2 (zeige STK3 Antikörper)/Lats1-induced phosphorylation of YAP (zeige YAP1 Antikörper) partially rescued the cells from apoptotic death.
Genome-wide location arrays in cell lines of various cell types revealed that Lats1 was a transcriptional target of CUX1 (zeige CUX1 Antikörper).
Our findings suggest that LATS1 is a potential candidate tumor suppressor and inhibits the growth and metastasis of gastric carcinoma cells via downregulation of the YAP (zeige YAP1 Antikörper) signaling.
Low LATS1 expression is associated with breast cancer.
Loss of LATS1 expression is associated with pancreatic cancer.
TNFAIP8 (zeige TNFAIP8 Antikörper) regulates Hippo (MST1 (zeige MST1 Antikörper)/2) signaling through its interaction with LATS1.
Lats1 SUMOylation at K751 suppresses its kinase activity and subsequently attenuates its tumor-suppressor functions in HepG2 cells.
High LATS1 expression is associated with Colorectal Tumorigenesis and Metastasis.
A group of miRNAs have been demonstrated to directly target components of the Hippo signaling pathway, such as YAP (zeige YAP1 Antikörper), TAZ (zeige TAZ Antikörper) and LATS1/2 in oncogenesis. (Review)
findings reveal a non-canonical (that is, YAP (zeige YAP1 Antikörper)/TAZ (zeige TAZ Antikörper)-independent) effect of LATS in the regulation of human breast cell fate
AGO2 (zeige EIF2C2 Antikörper) immunoprecipitation revealed LATS1 as a novel proapoptotic target of miR (zeige MLXIP Antikörper)-21 in T cells.
LATS1 was downregulated in cervical cancer and may suppress cell growth and invasion through regulating the expression of cyclin E (zeige CCNE1 Antikörper), p27 (zeige PAK2 Antikörper), MMP9 (zeige MMP9 Antikörper) and YAP (zeige YAP1 Antikörper).
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments.
large tumor suppressor
, serine/threonine-protein kinase LATS1
, LATS homolog 1
, LATS, large tumor suppressor, homolog 1
, LATS, large tumor suppressor, homolog 1 (Drosophila)
, serine/threonine-protein kinase LATS1-like
, WARTS protein kinase
, large tumor suppressor homolog 1
, large tumor supressor, homolog 1
, LATS (large tumor suppressor, Drosophila) homolog 1
, large tumor suppressor 1